Compare ANIK & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANIK | GLSI |
|---|---|---|
| Founded | 1983 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 142.5M | 123.9M |
| IPO Year | 1993 | 2020 |
| Metric | ANIK | GLSI |
|---|---|---|
| Price | $9.45 | $13.64 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $16.00 | ★ $39.00 |
| AVG Volume (30 Days) | 170.5K | ★ 342.7K |
| Earning Date | 11-05-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $112,806,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.79 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 30.55 | N/A |
| 52 Week Low | $7.87 | $7.78 |
| 52 Week High | $18.37 | $14.47 |
| Indicator | ANIK | GLSI |
|---|---|---|
| Relative Strength Index (RSI) | 44.48 | 79.42 |
| Support Level | $9.36 | $10.00 |
| Resistance Level | $9.82 | $14.01 |
| Average True Range (ATR) | 0.21 | 1.18 |
| MACD | -0.02 | 0.45 |
| Stochastic Oscillator | 15.22 | 90.78 |
Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States and also has its presence in Europe and Other countries.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.